ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.798,69
-1,30%
S&P 500
5.198,76
0,21%
US Dollar vs BRL
5,1535
1,26%
Bitcoin
62.162,87
1,59%
Brent Oil
83,475
-0,10%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NYSE
  6. ADC Therapeutics SA (ADCT)

  7. ADC Therapeutics SA (ADCT) Notícias

ADCT

ADC Therapeutics (ADCT)

ADC Therapeutics SA
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NYSE:ADCT
DataHoraFonteTítuloCódigoCompanhia
09/05/202408:15GlobeNewswire Inc.ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare ConferenceNYSE:ADCTADC Therapeutics SA
08/05/202417:07Edgar (US Regulatory)Form 8-K - Current reportNYSE:ADCTADC Therapeutics SA
07/05/202417:06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:ADCTADC Therapeutics SA
07/05/202417:02Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:ADCTADC Therapeutics SA
06/05/202408:30GlobeNewswire Inc.ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded WarrantsNYSE:ADCTADC Therapeutics SA
06/05/202407:38Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:ADCTADC Therapeutics SA
06/05/202407:10GlobeNewswire Inc.ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesNYSE:ADCTADC Therapeutics SA
06/05/202407:00GlobeNewswire Inc.ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone LymphomaNYSE:ADCTADC Therapeutics SA
01/05/202417:05GlobeNewswire Inc.ADC Therapeutics Makes Grants to New Employees Under Inducement PlanNYSE:ADCTADC Therapeutics SA
01/05/202408:00GlobeNewswire Inc.ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024NYSE:ADCTADC Therapeutics SA
04/04/202408:00GlobeNewswire Inc.ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin LymphomaNYSE:ADCTADC Therapeutics SA
03/04/202408:00GlobeNewswire Inc.ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024NYSE:ADCTADC Therapeutics SA
13/03/202408:03IH Market NewsMixed Futures Amidst Quiet Economic Schedule; Oil Prices ClimbNYSE:ADCTADC Therapeutics SA
13/03/202408:00GlobeNewswire Inc.ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesNYSE:ADCTADC Therapeutics SA
06/03/202409:15GlobeNewswire Inc.ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes SummitNYSE:ADCTADC Therapeutics SA
06/03/202409:00GlobeNewswire Inc.ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024NYSE:ADCTADC Therapeutics SA
05/03/202419:45GlobeNewswire Inc.ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual MeetingNYSE:ADCTADC Therapeutics SA
27/02/202409:00GlobeNewswire Inc.ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceNYSE:ADCTADC Therapeutics SA
04/01/202409:15GlobeNewswire Inc.ADC Therapeutics Regains Compliance with NYSE Continued Listing StandardsNYSE:ADCTADC Therapeutics SA
04/01/202409:00GlobeNewswire Inc.ADC Therapeutics Provides Business UpdatesNYSE:ADCTADC Therapeutics SA
02/01/202422:10Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:ADCTADC Therapeutics SA
19/12/202309:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:ADCTADC Therapeutics SA
18/12/202318:25Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNYSE:ADCTADC Therapeutics SA
12/12/202307:15GlobeNewswire Inc.ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)NYSE:ADCTADC Therapeutics SA
20/11/202304:40PR Newswire (US)Sobi to present new data at ASH 2023 Annual MeetingNYSE:ADCTADC Therapeutics SA
15/11/202305:00GlobeNewswire Inc.Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of DirectorsNYSE:ADCTADC Therapeutics SA
07/11/202309:15GlobeNewswire Inc.ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing StandardsNYSE:ADCTADC Therapeutics SA
07/11/202309:00GlobeNewswire Inc.ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdatesNYSE:ADCTADC Therapeutics SA
06/11/202309:00GlobeNewswire Inc.ADC Therapeutics to Participate in the Jefferies London Healthcare ConferenceNYSE:ADCTADC Therapeutics SA
02/11/202311:10GlobeNewswire Inc.ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual MeetingNYSE:ADCTADC Therapeutics SA
 Apresentando as notícias mais relevantes sobre:NYSE:ADCT

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
COGN3
COGNA ON
BOV
OIBR3
OI ON
BOV
PDTC3
Padtec ON
BOV
AZEV4
AZEVEDO PN
BOV
BHIA3
Grupo Casas Bahia ON
BOV
PRIO3
PETRORIO ON
BOV
HBRE3
HBR Realty Empreendiment... ON
BOV
VVEO3
CM Hospitalar ON
BOV
ENJU3
Enjoei ON
BOV
IFCM3
Infracommerce Caxaas ON
BOV
SGPS3
SPRINGS ON
BOV
ENAT3
ENAUTA ON
BOV
JHSF3
JHSF PART ON
BOV
BRKM5
BRASKEM PNA
BOV
FNAM11
Fundo Invest Amazonia Fi...
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados